FDA's Peter Marks shares more on CAR-T secondary cancer probe

FDA's Peter Marks shares more on CAR-T secondary cancer probe

Upworthy

Published

Three months after launching an investigation into the risk of patients developing secondary T-cell cancers after receiving a CAR-T drug, the FDA has shared more information on the cases it has seen so far. As of the end of 2023, the FDA noticed 22 cases of T-cell cancers following treatment with…

#fda #petermarks #phd #nicoleverdun #tecartus #gilead #yescarta #bristolmyerssquibbs #johnsonjohnson #novartis

Full Article